Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1063955

	registered interest
	date	19/02/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	General Practitioners: Overseas Companies
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what proportion of GP practices are administered by healthcare companies based abroad.
	tabling member constituency	York Outer
	tabling member printed	Julian Sturdy
	uin	223127
	answer	answer is ministerial correction date of answer 26/02/2019 answer text <p>This information is not collected or held centrally.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 223130 question first answered 26/02/2019 15:35:55 answering member 4067 label Biography information for Steve Brine
	tabling member	4079 label Biography information for Julian Sturdy

1063958

	registered interest
	date	19/02/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	General Practitioners: Overseas Companies
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what estimate he has made of the number of GP consortia that are run for profit by overseas-based medical insurance firms.
	tabling member constituency	York Outer
	tabling member printed	Julian Sturdy
	uin	223130
	answer	answer is ministerial correction date of answer 26/02/2019 answer text <p>This information is not collected or held centrally.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 223127 question first answered 26/02/2019 15:35:55 answering member 4067 label Biography information for Steve Brine
	tabling member	4079 label Biography information for Julian Sturdy

1083525

	registered interest
	date	07/03/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Diabetes: Medical Equipment
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent steps he has taken to widen access to blood glucose monitoring technology for diabetes patients.
	tabling member constituency	York Outer
	tabling member printed	Julian Sturdy
	uin	229721
	answer	answer is ministerial correction date of answer 15/03/2019 answer text <p>Glucose monitoring technology, such as continuous glucose monitoring or blood glucose test strips, will continue to be available to those meeting the relevant clinical criteria.</p><p> </p><p>In November 2018, NHS England announced that it will ensure that flash glucose monitoring is available on prescription for all patients who qualify for it in line with current recommendations. From April 2019, all qualifying patients will be able to receive it from their local general practitioner or diabetes team.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 15/03/2019 12:24:05 answering member 4067 label Biography information for Steve Brine
	tabling member	4079 label Biography information for Julian Sturdy

1029362

	registered interest
	date	20/12/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Life Expectancy
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent assessment he has made of trends in life expectancy.
	tabling member constituency	York Central
	tabling member printed	Rachael Maskell
	uin	204558
	answer	answer is ministerial correction date of answer 11/01/2019 answer text <p>Public Health England (PHE) was commissioned by the Department in 2018 to review trends in life expectancy and mortality in England. PHE’s review was released on 11 December 2018 and is available at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/recent-trends-in-mortality-in-england-review-and-data-packs" target="_blank">https://www.gov.uk/government/publications/recent-trends-in-mortality-in-england-review-and-data-packs</a></p><p> </p><p>The review summarises the findings from the commission and suggests further work that could be undertaken, by PHE or others. It provides a review of official data to advance understanding of the trends in life expectancy and mortality in England, as well as more detail on specific population groups and specific causes of death, including insight into possible explanations for the trends observed.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 11/01/2019 12:10:18 answering member 4067 label Biography information for Steve Brine
	tabling member	4471 label Biography information for Rachael Maskell

1029374

	registered interest
	date	20/12/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Babylon Health
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent meetings he has had with Babylon Healthcare.
	tabling member constituency	York Central
	tabling member printed	Rachael Maskell
	uin	204568
	answer	answer is ministerial correction date of answer 11/01/2019 answer text <p>My Rt. hon. Friend the Secretary of State for Health and Social Care has met Babylon Healthcare on two occasions including at a technology roundtable attended by various health technology companies on 18 July 2018 and at their offices on 13 September 2018.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 11/01/2019 12:07:13 answering member 4067 label Biography information for Steve Brine
	tabling member	4471 label Biography information for Rachael Maskell

1059803

	registered interest
	date	12/02/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Respiratory System: Staff
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether he plans to collect data on the regional primary-care respiratory workforce in the NHS to address the long-term respiratory workforce challenge identified in the NHS Long Term Plan.
	tabling member constituency	Wythenshawe and Sale East
	tabling member printed	Mike Kane
	uin	220250
	answer	answer is ministerial correction date of answer 18/02/2019 answer text <p>Following the publication of the NHS Long Term Plan, the National Implementation Framework, to be published in the spring, will provide further information on how the Long Term Plan will be implemented. Additional details, based on local health system five year plans, will be brought together in a detailed national implementation plan in the autumn.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 18/02/2019 17:23:56 answering member 4067 label Biography information for Steve Brine
	tabling member	4316 label Biography information for Mike Kane

1050071

	registered interest
	date	28/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Dementia
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to page 15 of the NHS Long Term Plan, published in January 2019, whether the revised GP Quality Outcomes Framework (QOF) proposed in that plan will effect QOF indicators for dementia including (a) new diagnoses, (b) care plans or memory assessment reviews and (c) named carers on records.
	tabling member constituency	Worsley and Eccles South
	tabling member printed	Barbara Keeley
	uin	213303
	answer	answer is ministerial correction date of answer 05/02/2019 answer text <p>Major reform to the GP contract was announced at the NHS England Board meeting on 31 January 2019, which sets out significant investment in general practice, including a focus upon improving care to some of the most vulnerable patients through a multidisciplinary approach. Further information is available at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/gp/gpfv/investment/gp-contract/" target="_blank">https://www.england.nhs.uk/gp/gpfv/investment/gp-contract/</a></p><p> </p><p>It also included changes to the Quality Outcomes Framework (QOF), reflecting the recommendations of the QOF Review published by NHS England in July 2018 is available at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2018/07/quality-outcome-framework-report-of-the-review.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2018/07/quality-outcome-framework-report-of-the-review.pdf</a></p><p> </p><p>Key changes to the QOF include:</p><p>- The retirement of 28 indicators which are either no longer in line with National Institute for Health and Care Excellence guidance, suffer from known measurement problems (usually because of small numbers at a practice level) or represent core general practice activities (175 points);</p><p>- The introduction of 15 new indicators in relation to blood pressure management, diabetes, cervical screening, chronic obstructive pulmonary disease and mental health (101 points). These should lead to improvements in patient care and ultimately outcomes;</p><p>- The replacement of exception reporting with a personalised care adjustment which recognises the necessity for practices to be able to tailor care to individual patients; and</p><p>- The introduction of a quality improvement domain worth 74 points in 2019/20 and, in the first year, focused upon prescribing safety and end of life care.</p><p> </p><p>A number of further reviews of the QOF domains are planned, including that for mental health. In relation to dementia specifically, the current indicator DEM005 (pre-diagnosis blood tests) will be retired due to the small numbers at practice level. This decision is in line with the recommendations of the QOF review. There are no changes to the other two dementia care indicators which focus upon identification and care planning.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 05/02/2019 15:12:42 answering member 4067 label Biography information for Steve Brine
	tabling member	1588 label Biography information for Barbara Keeley

1050072

	registered interest
	date	28/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Preventive Medicine
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to 63 of the NHS Long Term Plan, published in January 2019, what estimate he has made of the number of the target 150,000 cases of heart attack, stroke and dementia to be prevented that will be cases of (a) heart attacks, (b) strokes and (c) dementia; and whether any interim targets will be set over the ten year period of that plan.
	tabling member constituency	Worsley and Eccles South
	tabling member printed	Barbara Keeley
	uin	213304
	answer	answer is ministerial correction date of answer 05/02/2019 answer text <p>Cardiovascular disease (CVD) prevention and management are key priorities for NHS England, and as such the NHS Long Term Plan contains details of a number of important measures in relation to CVD. A key milestone in the CVD section of the NHS Long Term Plan is that the National Health Service will help prevent up to 150,000 heart attacks, strokes and dementia cases over the next 10 years.</p><p> </p><p>The National Implementation Framework, to be published in the spring, will provide further information on how the NHS Long Term Plan will be implemented. Additional details, based on local health system five year plans, will be brought together in a detailed national implementation plan in the autumn.</p><p> </p><p>NHS England will continue to work closely with key partners and stakeholders, including the British Heart Foundation, Stroke Association, Alzheimer’s Society and other voluntary sector partners, as it supports the NHS to deliver the commitments set out in the NHS Long Term Plan.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 05/02/2019 15:22:49 answering member 4067 label Biography information for Steve Brine
	tabling member	1588 label Biography information for Barbara Keeley

1037967

	registered interest
	date	08/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	CJD
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve diagnosis rates of sporadic Creutzfeldt-Jakob disease.
	tabling member constituency	Witham
	tabling member printed	Priti Patel
	uin	206318
	answer	answer is ministerial correction date of answer 16/01/2019 answer text <p>Early diagnosis of sporadic Creutzfeldt-Jakob Disease (sCJD) is challenging as the disorder is rare, and symptoms are non-specific, mimicking those seen in more common neurodegenerative, neuroinflammatory, and infectious disorders. Rapidity of progression and lack of response to treatment often leads clinicians to suspect a CJD diagnosis.</p><p> </p><p>The Department and the Scottish Government fund the National CJD Research and Surveillance Unit (NCJDRSU) to provide inter-disciplinary clinical and laboratory expertise (neurology, neuroradiology, neuropathology, biochemistry, and epidemiology) enabling early and accurate diagnosis of CJD. Clinicians from across the United Kingdom can discuss cases at any time. Highly trained specialists assess suspected cases locally within five days of referral and conduct structured assessments (clinical history, examination, and review of investigation results) before establishing diagnoses based on validated criteria. A consultant neuroradiologist at the NCJDRSU assesses neuroimaging for patients throughout the UK with a suspicion of CJD. The unit also provides a national diagnostic cerebrospinal fluid (CSF) 14-3-3/RT-QuIC service and will arrange collection of CSF samples with prompt results. Information on how clinicians can refer cases to the NCJDRSU is available at the following link:</p><p> </p><p><a href="http://www.cjd.ed.ac.uk/surveillance/referral-system" target="_blank">http://www.cjd.ed.ac.uk/surveillance/referral-system</a></p><p> </p><p>The Department and the Scottish Government have funded the development of diagnostic tests that combined with improved interpretation of neuroimaging has improved diagnostic accuracy.</p><p> </p><p>The NCJDRSU collects data on the number of people diagnosed with sCJD in the UK; break downs by of data for smaller geographies are not published. The following table shows a breakdown of the number of individuals, by year of death between 2014 and 2017. Date of diagnosis are considered synonymous for the purpose of reporting.</p><p> </p><p>Number of sCJD 2014-18 in the UK by year of death (as at January 2019).</p><table><tbody><tr><td><p>Year of death</p></td><td><p>Number</p></td></tr><tr><td><p>2014</p></td><td><p>99</p></td></tr><tr><td><p>2015</p></td><td><p>105</p></td></tr><tr><td><p>2016</p></td><td><p>119</p></td></tr><tr><td><p>2017</p></td><td><p>120</p></td></tr><tr><td><p>2018</p></td><td><p>125</p></td></tr></tbody></table><p>Source: NCJDRSU: <a href="https://www.cjd.ed.ac.uk/sites/default/files/figs.pdf" target="_blank">https://www.cjd.ed.ac.uk/sites/default/files/figs.pdf </a></p><p> </p><p>The NCJDRSU presents data regularly at clinical meetings and publishes in peer reviewed medical journals accessed by medical professionals, as well as producing a detailed annual report at the following link:</p><p> </p><p><a href="http://www.cjd.ed.ac.uk/sites/default/files/report26.pdf" target="_blank">http://www.cjd.ed.ac.uk/sites/default/files/report26.pdf</a></p><p> </p><p>The NCJDRSU website also provides information on the different types of CJD at the following link:</p><p> </p><p><a href="http://www.cjd.ed.ac.uk/surveillance/diagnosis-and-testing" target="_blank">http://www.cjd.ed.ac.uk/surveillance/diagnosis-and-testing</a></p><p> </p><p>sCJD is a rapidly progressive neurological disorder with an average time from first symptom onset to death of four months. The majority (88%) of individuals with sCJD over the past five years were assessed by clinicians from the NCJDRSU in life. After formal referral to NCJDRSU the average time to confirmation of the diagnosis was three days.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 206320 206323 206326 206327 question first answered 16/01/2019 15:05:48 answering member 4067 label Biography information for Steve Brine
	tabling member	4066 label Biography information for Priti Patel

1037969

	registered interest
	date	08/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	CJD
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that the symptoms of sporadic Creutzfeldt-Jakob disease are identified at the earliest opportunity.
	tabling member constituency	Witham
	tabling member printed	Priti Patel
	uin	206320
	answer	answer is ministerial correction date of answer 16/01/2019 answer text <p>Early diagnosis of sporadic Creutzfeldt-Jakob Disease (sCJD) is challenging as the disorder is rare, and symptoms are non-specific, mimicking those seen in more common neurodegenerative, neuroinflammatory, and infectious disorders. Rapidity of progression and lack of response to treatment often leads clinicians to suspect a CJD diagnosis.</p><p> </p><p>The Department and the Scottish Government fund the National CJD Research and Surveillance Unit (NCJDRSU) to provide inter-disciplinary clinical and laboratory expertise (neurology, neuroradiology, neuropathology, biochemistry, and epidemiology) enabling early and accurate diagnosis of CJD. Clinicians from across the United Kingdom can discuss cases at any time. Highly trained specialists assess suspected cases locally within five days of referral and conduct structured assessments (clinical history, examination, and review of investigation results) before establishing diagnoses based on validated criteria. A consultant neuroradiologist at the NCJDRSU assesses neuroimaging for patients throughout the UK with a suspicion of CJD. The unit also provides a national diagnostic cerebrospinal fluid (CSF) 14-3-3/RT-QuIC service and will arrange collection of CSF samples with prompt results. Information on how clinicians can refer cases to the NCJDRSU is available at the following link:</p><p> </p><p><a href="http://www.cjd.ed.ac.uk/surveillance/referral-system" target="_blank">http://www.cjd.ed.ac.uk/surveillance/referral-system</a></p><p> </p><p>The Department and the Scottish Government have funded the development of diagnostic tests that combined with improved interpretation of neuroimaging has improved diagnostic accuracy.</p><p> </p><p>The NCJDRSU collects data on the number of people diagnosed with sCJD in the UK; break downs by of data for smaller geographies are not published. The following table shows a breakdown of the number of individuals, by year of death between 2014 and 2017. Date of diagnosis are considered synonymous for the purpose of reporting.</p><p> </p><p>Number of sCJD 2014-18 in the UK by year of death (as at January 2019).</p><table><tbody><tr><td><p>Year of death</p></td><td><p>Number</p></td></tr><tr><td><p>2014</p></td><td><p>99</p></td></tr><tr><td><p>2015</p></td><td><p>105</p></td></tr><tr><td><p>2016</p></td><td><p>119</p></td></tr><tr><td><p>2017</p></td><td><p>120</p></td></tr><tr><td><p>2018</p></td><td><p>125</p></td></tr></tbody></table><p>Source: NCJDRSU: <a href="https://www.cjd.ed.ac.uk/sites/default/files/figs.pdf" target="_blank">https://www.cjd.ed.ac.uk/sites/default/files/figs.pdf </a></p><p> </p><p>The NCJDRSU presents data regularly at clinical meetings and publishes in peer reviewed medical journals accessed by medical professionals, as well as producing a detailed annual report at the following link:</p><p> </p><p><a href="http://www.cjd.ed.ac.uk/sites/default/files/report26.pdf" target="_blank">http://www.cjd.ed.ac.uk/sites/default/files/report26.pdf</a></p><p> </p><p>The NCJDRSU website also provides information on the different types of CJD at the following link:</p><p> </p><p><a href="http://www.cjd.ed.ac.uk/surveillance/diagnosis-and-testing" target="_blank">http://www.cjd.ed.ac.uk/surveillance/diagnosis-and-testing</a></p><p> </p><p>sCJD is a rapidly progressive neurological disorder with an average time from first symptom onset to death of four months. The majority (88%) of individuals with sCJD over the past five years were assessed by clinicians from the NCJDRSU in life. After formal referral to NCJDRSU the average time to confirmation of the diagnosis was three days.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 206318 206323 206326 206327 question first answered 16/01/2019 15:05:48 answering member 4067 label Biography information for Steve Brine
	tabling member	4066 label Biography information for Priti Patel